Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
US10221244B2 · kind B2 · utility
5Cited by
11References
31Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 18, 2017 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Aug 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.